Mitratapide

Mitratapide
Clinical data
Trade names	Yarvitan
Other names	Mitratapid; R103757
Routes of; administration	By mouth
ATCvet code	QA08AB90 (WHO) ;
Legal status
Legal status	CA: ℞-only;
Pharmacokinetic data
Bioavailability	55–69%
Protein binding	>99.9%[1]
Metabolism	Extensive liver (sulfoxidation); first pass effect
Elimination half-life	6.3 hours (mitratapide), up to 44.7 hours (metabolites)
Excretion	Feces (80–90%)[2]
Identifiers
	IUPAC name 2-[(2R)-Butan-2-yl]-4-[4-[4-[4-[[(2S,4R)-2-(4-chlorophenyl)-2-[(4-methyl-1,2,4-triazol-3-yl)sulfanylmethyl]-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one;
CAS Number	179602-65-4;
PubChem CID	213047;
ChemSpider	184740;
UNII	FVW7T75XP4;
KEGG	D05060;
Chemical and physical data
Formula	C36H41ClN8O4S
Molar mass	717.29 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC[C@@H](C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@@H]5CO[C@@](O5)(CSC6=NN=CN6C)C7=CC=C(C=C7)Cl;
	InChI InChI=1S/C36H41ClN8O4S/c1-4-26(2)45-35(46)44(25-39-45)31-11-9-29(10-12-31)42-17-19-43(20-18-42)30-13-15-32(16-14-30)47-21-33-22-48-36(49-33,27-5-7-28(37)8-6-27)23-50-34-40-38-24-41(34)3/h5-16,24-26,33H,4,17-23H2,1-3H3/t26-,33-,36-/m1/s1; Key:HQSRVYUCBOCBLY-XOOFNSLWSA-N;

Mitratapide is a veterinary medication used for the treatment of overweight and obese dogs sold under the brand name Yarvitan. Its mechanism of action involves inhibition of microsomal triglyceride transfer protein (MTP) which is responsible for the absorption of dietary lipids.[3] Clinical study also suggests that mitratapide may help to reverse insulin resistance in dogs.[4]

The drug was developed by Janssen Pharmaceutica and is chemically related to the antifungal drugs such as itraconazole which were also developed by Janssen.

Mitratapide (under the brand name Yarvitan) was authorized for use in the EU by the European Medicines Agency for helping weight loss in dogs, but it has since been withdrawn from the market in the EU.[5]

References

"Yarvitan 5 mg/ml Oral Solution for Dogs. Summary of Product Characteristics" (PDF). www.ema.europa.eu. Retrieved 27 August 2016.
"Yarvitan (mitratapide). Scientific Discussion" (PDF). www.ema.europa.eu. Retrieved 27 August 2016.
Mitratapide Archived 2012-04-05 at the Wayback Machine, vetstream.com
Dobenecker B, De Bock M, Engelen M, Goossens L, Scholz A, Kienzle E (December 2009). "Effect of mitratapide on body composition, body measurements and glucose tolerance in obese Beagles". Veterinary Research Communications. 33 (8): 839–47. doi:10.1007/s11259-009-9232-5. PMC 2776940. PMID 19544001.
German AJ (October 2016). "Weight management in obese pets: the tailoring concept and how it can improve results". Acta Veterinaria Scandinavica. 58 (Suppl 1): 57. doi:10.1186/s13028-016-0238-z. PMC 5073926. PMID 27766974.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] "Yarvitan 5 mg/ml Oral Solution for Dogs. Summary of Product Characteristics" (PDF). www.ema.europa.eu. Retrieved 27 August 2016.

[2] "Yarvitan (mitratapide). Scientific Discussion" (PDF). www.ema.europa.eu. Retrieved 27 August 2016.

[3] Mitratapide Archived 2012-04-05 at the Wayback Machine, vetstream.com

[4] Dobenecker B, De Bock M, Engelen M, Goossens L, Scholz A, Kienzle E (December 2009). "Effect of mitratapide on body composition, body measurements and glucose tolerance in obese Beagles". Veterinary Research Communications. 33 (8): 839–47. doi:10.1007/s11259-009-9232-5. PMC 2776940. PMID 19544001.

[German_2016-5] German AJ (October 2016). "Weight management in obese pets: the tailoring concept and how it can improve results". Acta Veterinaria Scandinavica. 58 (Suppl 1): 57. doi:10.1186/s13028-016-0238-z. PMC 5073926. PMID 27766974.